Benign Centrally-Located Intracranial Tumors
Conditions
Keywords
Hamartoma, Hypothalamic Hamartoma
Brief summary
The goal of this prospective, non-randomized, single-arm, feasibility study is to develop data to evaluate the safety and feasibility of ExAblate 4000 treatment of benign intracranial tumors which require clinical intervention in pediatric and young adult subjects. Indication of Use: Ablation of benign intracranial tumors in children and young adults which are ExAblate accessible.
Detailed description
The goal of this prospective, non-randomized, single-arm, feasibility study is to develop data to evaluate the safety and feasibility of ExAblate 4000 treatment of benign intracranial tumors which require clinical intervention in pediatric and young adult subjects. Indication of Use: Ablation of benign intracranial tumors in children and young adults which are ExAblate accessible. This is a feasibility study intended to collect data for use in the development of future studies. As such, no formal statistical hypothesis or hypothesis testing is proposed. The purpose of this study is to evaluate the safety and feasibility of managing benign brain tumor size using ExAblate 4000 treatment of progressing benign intracranial tumors which require clinical intervention in pediatric and young adult subjects.
Interventions
DEVICEExAblate 4000 System
Focused ultrasound
Sponsors
InSightec
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
5 Years to 22 Years
Healthy volunteers
No
Inclusion criteria
* Subjects with benign (WHO grade I) centrally located intracranial tumors which require clinical intervention and are known to carry minimal hemorrhage risk * Minimum head circumference will be 49cm * Skull Density Ratio (SDR) should be ≥0.35 * Subjects should be on a stable dose of all condition-related medications for 30 days prior to study entry as determine by medical records * Subjects and/or parent(s)/legal representative can provide accurate seizure diary log for the 30 days prior to FUS treatment and for the duration of the study
Exclusion criteria
* Subjects with unstable cardiac status that would increase anesthetic risk including * Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse as defined by the criteria outlined in the DSM-IV * Subjects who are taking human growth hormone (hGH), also known as somatotropin * Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including vagus nerve stimulator, responsive neurostimulator, cardiac pacemakers, non-metallic shunts, size limitations, etc. * Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or Magnevist) or sedative medications * Severely impaired renal function (estimated glomerular filtration rate \<70% of normal GFR for age) or receiving dialysis * Any history of clinically significant abnormal bleeding and/or coagulopathy * Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin, NSAIDs) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure; or, unable or unwilling to stop anticoagulant for the purpose of focused ultrasound procedure * Use of valproate derivatives for seizure control within the preceding 2 weeks * Known or suspected acute, active, or uncontrolled infection * History of postnatal stroke or intracranial hemorrhage within 6 months * Clinical suspicion of increased intracranial pressure (as evidenced by symptoms of obstruction: headache, nausea, vomiting, lethargy, and papilledema) * Have participated in another interventional trial in the last 30 days * History of immunocompromise, including subject who is HIV positive with incomplete viral suppression * Known life-threatening systemic disease * Subjects with suicidal ideation or previous suicide attempt within the past year * Subjects with malignant brain tumors, or the presence of any ambiguous clinical features that could imply a malignant potential to the tumor, or for which a biopsy is necessary * Subjects for whom histopathology is important for ongoing management * Female subjects who are pregnant, breast feeding or planning to become pregnant during the study or are unwilling to practice birth control during participation in the study, if of child-bearing age
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events Safety and Tolerability | Post ExAblate Procedure through 12 Month Follow-up | Safety will be assessed by tabulation of treatment related adverse events. All adverse events at least possibly procedure related will also be examined in detail for patterns of occurrence. |
| Measurement of Tumor Volume | Baseline through 12 Month Follow Up | ExAblate procedure will demonstrate feasibility along with measurement of tumor volumes at follow-up as compared to the baseline MRI. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the General Physical Exam | Baseline through 12 Month Follow Up | Any changes in physical examination performed by a physician. |
| Changes in the Neurological Exam | Baseline through 12 Month Follow Up | Any changes in neurological examination performed by the neurologist/neurosurgeon. |
| Confrontational Visual Field Testing | Baseline through 3 Month Follow Up | Changes in confrontational visual field testing performed by a physician |
| Global Impression of Change-Clinician | Day 1 through 12 Month Follow Up | Impression of change as the result of the treatment by a physician |
| Patient Global Impression of Change | Day 1 through 12 Month Follow Up | Impression of change as the result of the treatment by the subject |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJohn Ragheb, MD
Miami Children's Research Institute - Nicklaus Children's Hospital
Outcome results
None listed